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Background: Estrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki67 have been increasingly evaluated
by core needle biopsy (CNB) and are recommended for classifying breast cancer into molecular subtypes. However,
the concordance rate between CNB and open excision biopsy (OEB) has not been well documented.
Methods: Patients with paired CNB and OEB samples from Oct. 2009 to Feb. 2012 in Ruijin Hospital were included.
ER, PgR, HER2, and Ki67 were determined by immunohistochemistry (IHC). Patients with HER2 IHC 2+ were further
examined by FISH. Cutoff value for Ki67 high expression was 14%. Molecular subtypes were constructed as follows:
Luminal A, Luminal B, Triple Negative, and HER2 positive.
Results: There were 298 invasive breast cancer patients analyzed. Concordance rates for ER, PgR, and HER2 were
93.6%, 85.9%, and 96.3%, respectively. Ki67 expression was slightly higher in OEB than in CNB samples (29.3% vs. 26.8%,
P = 0.046). Good agreement (κ = 0.658) was demonstrated in evaluating molecular subtypes between CNB and OEB,
with a concordance rate of 77.2%. We also used a different Ki67 cutoff value (20%) for determining Luminal A and B
subtypes in HR (hormone receptor) +/HER2- diseases and the overall concordance rate was 79.2%. However, using a
cut-point of Ki67 either 14% or 20% for both specimens, there will be about 14% of HR+/HER2- specimens that are
called Luminal A on CNB and Luminal B on OEB.
Conclusion: CNB was accurate in determining ER, PgR, and HER2 status as well as non-Luminal molecular subtypes in
invasive breast cancer. Ki67 should be retested on OEB samples in HR+/HER2- patients to accurately distinguish
Luminal A from B tumors.
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Breast cancer is the most common malignancy affecting
women. However, the mortality has decreased in western
countries due to earlier diagnosis and more comprehensive
treatment [1]. The core needle biopsy (CNB) procedure is
almost as accurate as an open excision biopsy (OEB) in the
diagnosis of breast diseases, and is now widely taken as the
standard procedure for a breast cancer diagnosis [2].
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reproduction in any medium, provided the orbreast cancer clinical practice guideline required a pre-
operative disease-related staging, including pathological
examination of the CNB with a report on estrogen receptor
(ER), progesterone receptor (PgR), and human epidermal
growth factor receptor-2 (HER2) status by immunohisto-
chemistry (IHC) or fluorescence in situ hybridization
(FISH) [3]. A recent meta-analysis showed that CNB tissue
could replace OEB for determining ER, PgR, and HER2
status [4]. Breast cancer is a heterogeneous disease and
microarray expression data have demonstrated that there
are at least four subtypes of breast cancer, including
Luminal A, Luminal B, HER2positive, and basal-like
subtypes [5]. Practically, these subtypes can be approxi-
mated using clinicopathological markers rather than genetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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consensus also recommended that the IHC status of ER,
PgR, HER2, and Ki67 could be used to approximately
classify breast cancer into these subtypes, which can
guide subsequent systemic treatment [6]. However,
due to its relatively smaller sample size and tumor
heterogeneity, the biomarker assessment performed
on CNB samples may be less reliable than in OEB [7-9].
Little has been reported on the comparison of molecular
breast cancer subtype between CNB and OEB.
Therefore, using IHC and FISH to detect the ER, PgR,
HER2, and Ki67 status in CNB and subsequent OEB
samples, we then constructed breast cancer molecular
subtypes. Our aim was to estimate the concordance
between CNB and OEB in evaluating molecular subtypes
as well as the receptor status and Ki67 expression levels.
Methods
Patient population and samples
We retrospectively and consecutively analyzed patients with
paired CNB and OEB samples from Oct. 2009 to Feb. 2012
in Ruijin Hospital, Shanghai Jiaotong University School of
Medicine, Shanghai, China. All CNB were performed under
ultrasound guidance, with at least four 14-gauce core
biopsies being obtained for pathological examination.
Patients who met all the following criteria were included:
(1) received both CNB and OEB in our center; (2) found
invasive carcinoma in both CNB and OEB samples; (3)
female gender; (4) no preoperative therapy; (5) samples
available for IHC and FISH analysis; (6) HER2 IHC 2+
result further confirmed by FISH test. The study was
conducted in accordance with the Declaration of
Helsinki. The protocol was reviewed and approved by
the independent Ethical Committee/Institutional Review
Board of Ruijin Hospital, Shanghai Jiaotong University
School of Medicine, Shanghai, China.
Receptor status evaluation and molecular subtypes
classification
IHC assessment of ER (SP1, DAKO), PgR (PgR 636,
DAKO), Ki67 (MIB-1, DAKO) and HER2 (4B5, Roche)
were made from paraffin-embedded tumor samples from
CNB and OEB by Ventana autostain system, BenchMark
XT, and evaluated with internal and positive controls. All
IHC and FISH results were firstly retrospective collected
and then further reviewed by two senior pathologists
(Xiaochun Fei, and Xiaolong Jin, who diagnosed more
than 300 breast cancer patients per year and achieved as
high as 90% concordance rate in evaluating these IHC or
FISH results) for this study purpose. ER-positivity (ER+)
and PgR-positivity (PgR+) were defined as more than 1%
positive invasive tumor cells with nuclear staining [10].
HER2 was firstly determined by IHC and scored as 0 to 3
+ according to ASCO/CAP (American Society of ClinicalOncology/College of American Pathologists) guideline [11].
Samples with IHC HER2 2+ were further examined by FISH
and the tumor was considered to have HER2 amplification
if the ratio of HER2 gene signals to chromosome 17 signals
was ≥ 2.2. Tumors with HER2 IHC 3+ or FISH+were
regarded as HER2 positivity (HER2+). For Ki67 expression
scoring, we firstly reviewed the cell distribution over the
whole slice and used the same method for scoring CNB and
OEB samples. If Ki67 expression was uniformly distributed
over the entire slide, 500–2000 cells were chosen from dif-
ferent microscope views; otherwise, 2000 cells were equally
counted in both hotspot and negative areas in slice. Ki67
expression was scored as the percentage of positive invasive
tumor cells with any nuclear staining and recorded as mean
percentage of positive cells (Figure 1) [12]. All IHC and
FISH analyses were conducted in the Department of
Pathology, Ruijin Hospital, Shanghai Jiaotong University
School of Medicine, which participated in an external
quality control program and classified as “excellent” quality
by WHO-British UKNEQAS (United Kingdom National
External Quality Assessment Service) organization.
Hormonal receptor positivity (HR+) was defined as
either ER + or PgR+, and HR– as both ER– and PgR–. To
determine the Luminal status in HR+/HER2- tumors, the
cutoff value of Ki67 high expression was set as 14%. Thus,
there were four breast cancer subtypes as classified
according to the 2011 St. Gallen breast cancer consensus
[6]: Luminal A (HR+/HER2–, Ki67 low), Luminal B
(HR+/HER2-, Ki67 high or HR+/HER2+), triple nega-
tive (HR-/HER2–) and HER2 positive (HR-/HER2+).
We further subdivided our Luminal B cases into Luminal
B-HER2- (HR+/HER2-, Ki67 high) and Luminal-HER2+
(HR + and HER2+) subtypes. To mimic the actual and
convenient clinical practice situation, we also used 20% as
Ki67 cutoff value to classify Luminal A and B subtypes,
which was the mean value for HR+/HER2- patients and
median value for the whole patients in CNB samples.
Statistical analysis
Concordance analysis of receptor status and molecular
subtypes was performed on CNB and OEB samples.
Statistical analysis, including positive and negative agree-
ment, was calculated using kappa test. Values of κ > 0.6
were correlated with good agreement, values between 0.4
and 0.6 were considered as moderate agreement,
values <0.4 as fair, and values <0.2 as poor agreement
[13]. All statistical tests were two-sided and carried out at a
significance level of 0.05 using the SPSS statistical software
package (version 13.0; SPSS Company, Chicago, IL).
Results
Patient characteristics
There were 298 invasive breast cancer patients eligible
for this study. The median age was 54 (24–91) years.
A B C
Figure 1 Ki67 expression in breast cancer. A: positive Ki67 nuclei; B: faintly positive Ki67 nuclei; C: negative Ki67 nuclei.
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diagnosed as having negative axillary lymph nodes
(Table 1).
The expression rates of ER, PgR, HER2, and molecular
subtypes showed no significant difference between
CNB and OEB (Table 2). However, the mean Ki67
expression was slightly higher in OEB than in CNB
samples (P = 0.046), these being 29.3% and 26.8%,
respectively. Median Ki67 was 20% (1%-90%) for CNB sam-
ples in this cohort. Furthermore, in HR+/HER2- tumors,
the mean Ki67 value was also 20% in CNB samples.
Comparison of CNB with OEB for receptor status and
Ki67 results
Evaluation of ER expression on CNB samples had a 93.6%
concordance rate with ER results on OEB samples, with
good overall agreement (κ = 0.827). PgR and HER2Table 1 Baseline patient characteristics
Characteristic No. %









≤2 cm 123 41.3
2-5 cm 160 53.7
>5 cm 8 2.7
Axillary lymph node
Negative 165 55.4
1-3 + 76 25.5
≥4+ 55 18.5
Nx 2 0.7expression on CNB samples also revealed good agreement
with those on OEB samples; the overall concordance rates
were 85.9% and 96.3%, with κ value of 0.704 and 0.894,
respectively (Table 3). In addition, similar to the ER and
PgR results, a good agreement was observed in terms of
HR detection, with a concordance rate of 93.6% (κ = 0.824).
More Ki67 high expression tumors were detected on
OEB samples compared with those on CNB samples
(κ = 0.545). We further evaluated whether tumor size,
ER, PgR, HER2, and grade status had an effect on
Ki67 performance between CNB and OEB. 14% cutoff
value was used to define Ki67 high/low expression. ER,
PgR, HER2, and grade were detected on CNB samples.
There was no concordance rate difference between T1 and
T2 tumors, 77.2% in smaller tumors (T1 tumors, n = 123)
and 83.8% in larger tumors (T2 tumors, n = 160), with κ
value of 0.530 and 0.604, respectively. Also, HER2 status
had no impact on Ki67 detecting accurate. However, Ki67
concordance rate was much higher in ER negative
tumors compared with ER positive tumors (92.5% vs.
76.2%, P = 0.003). 60 patients with ER negative and
high Ki67 diseases had 100% Ki67 concordance rate
between CNB and OEB. Moreover, patients with PgR
negative, or grade 3 tumors had a better agreement
using CNB to detect Ki67 status than those with PgR
positive or grade 1–2 diseases, with P value 0.012 and
0.006, respectively.
Comparison of CNB with OEB for molecular subtypes
Table 4 shows concordance rates for molecular subtypes
between CNB and OEB. Using 14% as the Ki67 cutoff value
for determining Luminal A and B in HR+/HER2- disease,
32.6% of patients were classified as Luminal A in the CNB
samples compared with 26.8% in the surgical specimen. For
the remaining patients, 45.4%, 13.1% and 9.1% of cases were
respectively classified as Luminal B, triple negative,
and HER2 positive diseases using CNB specimens.
The concordance rate for detecting these four molecular
subtypes was 77.2% between CNB and OEB samples,
which also demonstrated as good agreement (κ = 0.658).
There were only 2 of the 39 triple negative patients
Table 2 Tumor characteristics for CNB and OEB results
Characteristic No. (%) P value
CNB OEB
Pathological type 0.190
Invasive ductal carcinoma 260 (87.2) 269 (90.3)
Invasive lobular carcinoma 12 (4.0) 11 (3.7)
Mixed carcinoma 11 (3.7) 3 (1.0)
Others 15 (5.0) 15 (5.0)
Histological grading 0.009
I 6 (2.0) 4 (1.3)
II 138 (46.3) 151 (50.7)
III 97 (32.6) 114 (38.3)
NA 57 (19.1) 29 (9.7)
Estrogen Receptor 0.294
Negative 67 (22.5) 78 (26.2)
Positive 231 (77.5) 220 (73.8)
Progesterone Receptor 0.502
Negative 120 (40.3) 112 (37.6)
Positive 178 (59.7) 186 (62.4)
HER2 0.768
Negative 233 (78.2) 230 (77.2)
Positive 65 (21.8) 68 (22.8)
Ki67 (%, mean) 26.8 (1-90) 29.3 (1-90) 0.046
<14 112 (37.6) 89 (29.9)
≥14 186 (62.4) 209 (70.1)
Hormonal receptor 0.386
Negative 66 (22.1) 75 (25.2)
Positive 232 (77.9) 223 (74.8)
Molecular subtype 0.484*
Luminal A 97 (32.6) 80 (26.8)
Luminal B 135 (45.4) 143 (48.0)
Luminal B (HER2-) 97 (32.6) 105 (35.2)
Luminal-HER2+ 38 (12.8) 38 (12.8)
Triple negative 39 (13.1) 45 (15.1)
HER2 positive 27 (9.1) 30 (10.1)
Abbreviation: CNB, core needle biopsy; OEB, open excision biopsy; NA,
not available;
*: calculated with four subtypes classification.
Table 3 Concordance between CNB and OEB for receptor





ER 93.6 0.827 <0.001
Negative 63 4
Positive 15 216
PgR 85.9 0.704 <0.001
Negative 95 25
Positive 17 161
HER2 96.3 0.894 <0.001
Negative 226 7
Positive 4 61
Ki67 <14% ≥14% 79.5 0.545 <0.001
<14% 70 42
≥14% 19 167
HR 93.6 0.824 <0.001
Negative 61 5
Positive 14 218
Abbreviation: CNB, core needle biopsy; OEB, open excision biopsy; ER, estrogen
receptor; PgR, progesterone receptor; HR, hormonal receptor.
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specimen. Furthermore, if we subdivided the Luminal B
subtype as Luminal B-HER2- and Luminal-HER2+ sub-
types according to HER2 status, a similar concordance rate
and agreement status was also found (Table 4).
To be more convenient for our clinical practice, we
used 20% as Ki67 cutoff value for determining Luminal
A and B subtypes in HR+/HER2- diseases, which was
also the mean value in HR+/HER2- patients and median
value for the whole population in CNB samples. Therewere 47.3% of the cases classified as Luminal A subtype in
the CNB samples. The overall concordance rates were
79.2% and 78.2% in terms of the four and five molecular
subtype classification, respectively. The κ values for these
two categories were 0.692 and 0.699, which were also
regarded as good agreement (Table 4). However, using a
cut-point of Ki67 either 14% or 20% for both specimens,
there will be about 14% of HR+/HER2- specimens would
be classified as Luminal A on CNB and Luminal B
on OEB, indicating Ki67 testing should be repeated in
OEB samples.
Discussion
To our knowledge, this is the first study to evaluate the
concordance of molecular subtypes between CNB and
subsequent OEB samples in large series of breast cancer
patients. In the present study, good agreement was
demonstrated in evaluating molecular subtypes as well
as ER, PgR and HER2 status between CNB and OEB
(κ > 0.6). Although, Ki67 expression was found to be
slightly higher in the OEB samples.
Concordance rates of 93.6% for ER, and 85.9% for PgR
showed a good correlation with these biomarkers
between CNB and OEB, similar to other studies, although
the ER concordance rate was relatively higher than with
PgR [9,14]. The main explanation may be poorer fixation of
OEB compared with CNB specimens, including delayed
fixation, under-fixation, and over-fixation with formalin
prior to IHC analysis, because the PgR test seems to require





Using Ki67 = 14% as cutoff value for determining Luminal A and B in HR+/HER2- diseases
4 Subtypes Luminal A Luminal B TNBC HER2+ 77.2 0.658 (<0.001)
Luminal A 65 32 0 0
Luminal B 15 106 7 7
TNBC 0 1 37 1
HER2+ 0 4 1 22
5 Subtypes Luminal A Luminal B TNBC HER2+ 75.8 0.679 (<0.001)
HER2- HER2+
Luminal A 65 31 1 0 0
Luminal B
HER2- 14 72 3 7 1
HER2+ 1 1 30 0 6
TNBC 1 0 0 37 1
HER2+ 0 0 4 1 22
Using Ki67 = 20% as cutoff value for determining Luminal A and B in HR+/HER2- diseases
4 Subtypes Luminal A Luminal B TNBC HER2+ 79.2 0.692 (<0.001)
Luminal A 110 31 0 0
Luminal B 10 67 7 7
TNBC 1 0 37 1
HER2+ 0 4 1 22
5 Subtypes Luminal A Luminal B TNBC HER2+ 78.2 0.699 (<0.001)
HER2- HER2+
Luminal A 110 29 2 0 0
Luminal B
HER2- 9 34 2 7 1
HER2+ 1 1 30 0 6
TNBC 1 0 0 37 1
HER2+ 0 0 4 1 22
Abbreviation: CNB, core needle biopsy; OEB, open excision biopsy; HR, hormonal receptor; TNBC, triple negative breast cancer.
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Another reason could be more heterogeneous distribution
within the tumor for PgR compared with ER detection [16].
In terms of HER2 examination, a 96.3% concordance
rate after adding FISH testing showed that detecting
HER2 on CNB samples was as sensitive in predicting HER2
status as OEB. Previous studies have reported concordance
rate between CNB and OEB for HER2 examination to be
about 90%. However, one study reported a false positive
rate of IHC testing on CNB samples as high as 19.3% [17].
A recent meta-analysis showed that the sensitivity and
specificity of HER2 status evaluation of CNB was 81% and
89%, respectively, with the HER2 positivity definition as
IHC 2+ or 3+ or FISH+. However, the specificity of HER2
detection in CNB would be improved with a very low false
positive rate (specificity 98%) using a HER2 positivitydefinition as IHC 3+ or FISH + [4]. In our cohort, we car-
ried out all FISH testing in IHC HER2 2+ cases, according
to the ASCO/ACP HER2 detection recommendation, most
likely explain our high concordance rate.
Ki67 antigen has been used to evaluate the proliferative
activity of breast cancer for several decades, and a meta-
analysis has shown that high Ki67 expression confers a
higher risk of relapse and a worse survival [18]. There was
an increasing debate about the lack of standardization of
Ki67 pathological interpretation and standard cutoff value
for Ki67 high expression. Published studies have used vari-
ous Ki67 cutoff value such as mean, median, the optimal
cut-off value or arbitrary values [18]. In the current study,
we used 20% (mean value in ER+/HER2- tumors and
median value for the whole patients on CNB) as another
Ki67 cutoff value (14%) for determining Luminal A and B
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International Research Group (BCIRG) 001 trial subgroup
analysis showed that Ki67 IHC results, whose cutoff value
was 14%, can define which ER+/HER2- tumors can get
more benefit from adjuvant docetaxel treatment [19].
Moreover, in PACS 01 trial, ER positive breast cancer
patients with Ki67 ≥ 20% were more sensitive to docetaxel
treatment in the adjuvant setting [20]. In patients with
advanced breast cancer, higher Ki67 levels have been
significantly associated with decreased time to aromatase
inhibitor treatment failure [21]. The comparison of base-
line Ki67 labeling index and post-treatment level would
enhance the informative value of the test in patients
received preoperative endocrine therapy [22]. Gene
expression profiling has revealed that the Ki-67 gene
seems to play an important role in several “proliferation
signatures” and can be assessed by the Ki67 index [23].
Furthermore, Ki67 is a key selected gene in the Oncotype
DXTM assay, which can be used to predict the outcome
and chemotherapy sensitivity in ER+/HER2- tumors
[24,25]. Thus, the 2011 St. Gallen breast cancer consensus
recommended that proliferation markers, such as Ki67,
can be applied to classify breast cancer into different
Luminal subtypes, guiding further treatment [6]. In our
study, we found moderate agreement (κ = 0.545) and a
slightly higher Ki67 expression in OEB samples compared
with CNB samples, with the mean Ki67 expression values
of 29.3% and 26.8%, respectively. A major reason for this
Ki67 expression difference may be due to sampling error
and tumor heterogeneity, as CNB might not reflect the
true status of the entire tumor [12]. However, we found
no improvement in Ki67 evaluation in smaller compared
with larger tumors. There is literature suggesting that four
cores can provide sufficient tumor for biomarker testing
and good diagnostic accuracy, meaning that Ki67 evalu-
ation might improve with increasing number of cores
[26]. However, the level of concordance between the CNB
and OEB improved only slightly with increasing number
of core passes, but reaching a plateau after 6 or more core
passes [27]. In addition, the concordance rates were much
higher for ER, PgR, and HER2 than Ki67, which again can
be explained by more heterogeneous distribution within
the tumor for Ki67, especially in ER/PR positive or grade
1–2 tumors. A comparison of immunocytochemical assays
for Ki67 and other biologic variables on preoperative fine-
needle aspirates with OBE results showed the concord-
ance between cytology and histology was the lowest for
Ki67 evaluation: 89% for ER, 78% for PgR, 79% for p53,
and 70% for Ki67, respectively [28]. In one study, Ki67 did
not discriminate different biological subtypes of disease
with distinct clinical courses rather describe the compos-
ition of the mixture of cells in the tumor, which also
reflected that the heterogeneity of breast cancer might
contribute to Ki67 scoring inconsistence [29]. Greer et al.compared the Ki67 expression between CNB and OEB by
IHC and showed a concordance rate of 73% with a κ value
of 0.48, similar with our result [27]. Our data indicate that,
due to heterogeneous distribution of the Ki67 antigen, CNB
may not adequately represent its true biologic profile and
Ki67 should be detected on both CNB and OEB in order to
avoid misclassifying tumor subtypes and omission of life-
saving systemic therapy, especially on HR+/HER2- tumors.
Breast cancer can no longer be considered as a single
disease [5,30]. Molecular subtypes can be defined by
microarray testing and this classification approximated
using IHC results of ER, PgR, HER2 and other prolifera-
tion biomarkers. In order to make an appropriate indi-
vidualized therapeutic strategy, management of breast
cancer according to these distinct subtypes is required.
CNB is being increasingly used for breast cancer diagno-
sis and translational research. However, there has been
no large published data about the agreement of these
molecular subtypes between CNB and OEB in breast
cancer. In the current study, with a large series of breast
cancer patients, we found good agreement in evaluating
molecular subtypes on CNB compared with those on OEB
samples (κ = 0.658). Furthermore, a high concordance rate
was also detected if by subdividing Luminal B subtype into
Luminal B-HER2- and Luminal-HER2+ subtypes. How-
ever, approximately 14% of HR+/HER2- specimens would
be classified as Luminal A on CNB and Luminal B on
OEB, thus depriving these patients of potentially helpful
chemotherapy. In summary, our results show a high
concordance rate and good agreement between CNB and
OEB in the distinction between Luminal and non-Luminal
molecular subtypes. However, the differentiation of
Luminal A from Luminal B in HR+/HER2- patients is less
accurate due to intra-tumoral heterogeneity of Ki67.
Conclusion
CNB had good agreement in evaluating molecular subtypes
as well as ER, PgR, and HER2 status in breast cancer.
Due to inherent Ki67 heterogeneity ER+/HER2- tumors,
distinguishing Luminal A from Luminal B is less accurate;
thus Ki67 ought to be examined both on CNB and OEB
samples, especially in HR+/HER2- tumors. Our findings
support the recommendation that CNBis considered
the initial procedure to assess molecular subtypes and
receptor status in invasive breast cancer.
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